echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Nature Medincine: The first human active infection challenge test with the new coronavirus, revealing the attack and transmission mode of the new coronavirus

    Nature Medincine: The first human active infection challenge test with the new coronavirus, revealing the attack and transmission mode of the new coronavirus

    • Last Update: 2022-04-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, a new round of new crown epidemics appeared in Shanghai and Jilin and other places.


    Researchers from Imperial College London published a research paper titled: Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in youngadults in thetop international medical journal Nature Medincine


    Nature Medincine

    The study recruited 36 young, healthy volunteers to participate in the first-ever COVID-19 challenge study in humans


    In the first human new crown challenge study , 18 people were infected, all of which were mild.


    A droplet smaller than 10 microns "fired" by a person infected with the new crown through a cough or sneeze is enough to infect a person, and it only takes two days for a person to start spreading the virus after being infected


    For many years, controlled human infection models (CHIMs) have been used to study disease pathogenesis and to evaluate preventive and therapeutic approaches


    In fact, as early as March 2020, researchers from Rutgers University, Harvard T.


    Once the article was published, it caused widespread controversy


    In young people, infection with Covid-19 is often mild or asymptomatic, but this may drive community transmission, although the detailed time course and contagiousness of early infection are not fully understood


    In this latest study, the research team recruited 36 healthy adults aged 18-29 to participate in the challenge trial.


    Research flow chart

    Of the 34 seronegative volunteers, 18 (53%) were infected, the viral load peaked 5 days after vaccination, and all infected individuals developed SARS-CoV-2-specific IgG and neutralizing antibodies


    What's more, the study found that the volunteers spread the virus for an average of 6.


    The volunteers spread the virus for an average of 6.


    Virus transmission peaks rapidly after a short incubation period after infection

    Of the 18 infected, 2 (11%) were asymptomatic, and most of the others had mild symptoms.


    About 83% of patients lost their sense of smell

    Human COVID-19 challenge can induce mild to moderate symptoms

    Now, the research team plans to conduct another challenging study in a vaccinated population infected with the Delta mutant strain


    Dr Christopher Chiu , the study's corresponding author , said: "In fact, no other type of study has done this, because often patients only pay attention when they develop symptoms, so early signs of infection are often missed.


    Christopher Chiu

    In conclusion, this study establishes the viral dynamics during the initial and early infection of 2019-nCoV through the detailed description and safety analysis of the first-ever 2019-nCoV infection challenge study in young healthy adults, and public health recommendations and strategies for 2019-nCoV transmission.
    Control strategy has far-reaching effects
    .

    It is worth noting that these "human challenge studies" are controversial because they carry certain risks - does direct infection with the new coronavirus pose unpredictable dangers to volunteers? In addition, it remains to be verified whether such a small-scale trial with a highly controlled and uniform nature can be generalized to the population
    .

    These "human challenge studies" are controversial because they carry certain risks - does direct infection with the new coronavirus pose unpredictable dangers to volunteers? In addition, it remains to be verified whether such a small-scale trial with a highly controlled and uniform nature can be generalized to the population
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.